The Effect of Alpha-lactalbumin on Microbiota Composition
Primary Purpose
Alpha-lactalbumin, Microbiota, Dysbiosis
Status
Active
Phase
Not Applicable
Locations
Italy
Study Type
Interventional
Intervention
Alpha-lactalbumin
Sponsored by
About this trial
This is an interventional supportive care trial for Alpha-lactalbumin
Eligibility Criteria
Inclusion Criteria: condition of dysbiosis Exclusion Criteria: antibiotic treatment within 1 month probiotic or prebiotic treatments concomitant inflammatory intestinal diseases pregnancy neoplastic diseases allergy to milk protein (Alpha-lactalbumin) substance abuse
Sites / Locations
- Centro Polispecialistico Giovanni Paolo I°
Arms of the Study
Arm 1
Arm Type
Experimental
Arm Label
Alpha-lactalbumin
Arm Description
Outcomes
Primary Outcome Measures
Improvement of microbiota composition
Determination of bacterial biodiversity by metagenomics approach
Secondary Outcome Measures
Full Information
NCT ID
NCT05674318
First Posted
December 21, 2022
Last Updated
September 13, 2023
Sponsor
Lo.Li.Pharma s.r.l
1. Study Identification
Unique Protocol Identification Number
NCT05674318
Brief Title
The Effect of Alpha-lactalbumin on Microbiota Composition
Official Title
Evaluation of Prebiotic Effects of Alpha-lactalbumin on Microbiota Composition
Study Type
Interventional
2. Study Status
Record Verification Date
June 2023
Overall Recruitment Status
Active, not recruiting
Study Start Date
January 30, 2023 (Actual)
Primary Completion Date
September 30, 2023 (Anticipated)
Study Completion Date
October 30, 2023 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Lo.Li.Pharma s.r.l
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
5. Study Description
Brief Summary
To evaluate the effects on microbiota composition after the administration of an oral supplementation based on Alpha-lactalbumin in subjects with dysbiosis.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Alpha-lactalbumin, Microbiota, Dysbiosis
7. Study Design
Primary Purpose
Supportive Care
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
10 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Alpha-lactalbumin
Arm Type
Experimental
Intervention Type
Dietary Supplement
Intervention Name(s)
Alpha-lactalbumin
Intervention Description
Oral assumption of two tabs/day containing Alpha-lactalbumin for 30 days
Primary Outcome Measure Information:
Title
Improvement of microbiota composition
Description
Determination of bacterial biodiversity by metagenomics approach
Time Frame
Change from baseline microbiota composition to 30 days of treatment
10. Eligibility
Sex
All
Minimum Age & Unit of Time
25 Years
Maximum Age & Unit of Time
50 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
condition of dysbiosis
Exclusion Criteria:
antibiotic treatment within 1 month
probiotic or prebiotic treatments
concomitant inflammatory intestinal diseases
pregnancy
neoplastic diseases
allergy to milk protein (Alpha-lactalbumin)
substance abuse
Facility Information:
Facility Name
Centro Polispecialistico Giovanni Paolo I°
City
Viterbo
State/Province
Rome
ZIP/Postal Code
01100
Country
Italy
12. IPD Sharing Statement
Learn more about this trial
The Effect of Alpha-lactalbumin on Microbiota Composition
We'll reach out to this number within 24 hrs